 Krystal Biotech, Inc. KRYS, a gene therapy company dedicated to developing transformative medicines to treat diseases caused by protein or gene dysfunction, today announced interim results for a first-in-human Phase 12 placebo controlled clinical trial evaluating topical administration of KB105 in patients with autosomal recessive congenital ichthyosis ARCI being presented at the Society for Investigative Dermatology SID annual meeting. Following todays results, Krystal plans to enroll pediatric patients in the Phase 2 portion of the clinical trial. 